Latest / The Dales Report | Trade to Black
Psychedelic Stock MindMed: Investor Anticipation Rising | TDR Small Cap Sunday
On our latest Small Cap Sunday podcast, we profile MindMed (NASDAQ: MDMD), an industry leader in the psychedelic space. We’ll review what the company accomplished in 2024, and what investors can anticipate hearing into 2p25. In 2024, MindMed made significant announcements, including the dosing of the first patient in their Phase 3 Voyage study of MM120 for Generalized Anxiety Disorder (GAD) on December 16. This study aims to assess the efficacy and safety of MM120 ODT versus placebo, involving around 200 participants in the U.S. MindMed's share price has fluctuated throughout the year…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.